CMS Grants Pass-Through Status for Lantheus' PYLARIFY TruVu
LNTH has more than doubled off its 52-week low of $49.67.
Summary
CMS granted Transitional Pass-Through payment status and a permanent HCPCS code for PYLARIFY TruVu, effective October 1, 2026. This enables separate reimbursement in hospital outpatient settings, supporting the commercial launch of the new PSMA PET imaging formulation. The designation builds on the existing PYLARIFY franchise, which has been used in over 900,000 scans. Lantheus expects a phased geographic rollout to improve manufacturing efficiency and supply flexibility. This follows the FDA approval of BRAVNETSA last week and comes ahead of the October 14 shareholder vote on the $8B Curium acquisition.
At the time of this announcement, LNTH was trading at $99.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $49.67 to $111.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.